[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity

Rhea-AI Filing Summary

Protagonist Therapeutics director Bryan Giraudo reported exercising stock options and selling shares of common stock. On May 7, he exercised options for 36,000 shares at exercise prices of $6.45 and $6.98 per share and sold 36,000 directly held shares at about $100.14 per share. The Bryan & Courtney Giraudo Trust sold an additional 12,000 shares that day at about $100.07 per share.

On May 8, Giraudo sold 5,130 directly held shares at $100.00 per share, and the trust sold another 6,000 shares at $100.00 per share. A footnote states these sales occurred at prices ranging from $98.69 to $104.67. After these transactions, he holds 12,695 shares of Protagonist Therapeutics common stock directly, and the trust no longer holds shares from these reported transactions. All reported stock options are shown as fully exercised, with no remaining derivative holdings in this filing.

Insider Trade Summary

Net Seller: 59,130 shares ($5,918,880)

Net Sell 8 txns

Insider Giraudo Bryan

Role null

Sold 59,130 shs ($5.92M)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,000	$100.00	$600K
Sale	Common Stock	5,130	$100.00	$513K
Exercise	Stock Option (right to buy)	24,000	$0.00	--
Exercise	Stock Option (right to buy)	12,000	$0.00	--
Exercise	Common Stock	24,000	$6.45	$155K
Exercise	Common Stock	12,000	$6.98	$84K
Sale	Common Stock	36,000	$100.14	$3.61M
Sale	Common Stock	12,000	$100.07	$1.20M

Holdings After Transaction: Common Stock — 0 shares (Indirect, By Bryan & Courtney Giraudo Trust); Common Stock — 12,695 shares (Direct, null); Stock Option (right to buy) — 0 shares (Direct, null)

Footnotes (1)

1. Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.69 to $104.67. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These stock options are fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Giraudo Bryan

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CALIFORNIA 94560-1160

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026		M		24,000	A	$6.45	31,825(1)	D
Common Stock	05/07/2026		M		12,000	A	$6.98	43,825	D
Common Stock	05/07/2026		S		36,000	D	$100.14(2)	27,825	D
Common Stock	05/07/2026		S		12,000	D	$100.07	6,000(1)	I	By Bryan & Courtney Giraudo Trust
Common Stock	05/08/2026		S		6,000	D	$100	0	I	By Bryan & Courtney Giraudo Trust
Common Stock	05/08/2026		S		5,130	D	$100	12,695	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.45	05/07/2026		M			24,000	(3)	05/14/2028	Common Stock	24,000	$0	0	D
Stock Option (right to buy)	$6.98	05/07/2026		M			12,000	(3)	05/28/2028	Common Stock	12,000	$0	0	D

Explanation of Responses:

1. Reflects 10,000 shares of common stock that were previously held directly by the Reporting Person and which were transferred to the Bryan & Courtney Giraudo Trust.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $98.69 to $104.67. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. These stock options are fully vested.

	/s/ Matthew Gosling, Attorney-in-Fact for Bryan Giraudo	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)